Rescue pre-operative treatment with Lugol's solution in uncontrolled Graves' disease

Jan Calissendorff, Henrik Falhammar, Jan Calissendorff, Henrik Falhammar

Abstract

Background: Graves' disease is a common cause of hyperthyroidism. Three therapies have been used for decades: pharmacologic therapy, surgery and radioiodine. In case of adverse events, especially agranulocytosis or hepatotoxicity, pre-treatment with Lugol's solution containing iodine/potassium iodide to induce euthyroidism before surgery could be advocated, but this has rarely been reported.

Methods: All patients hospitalised due to uncontrolled hyperthyroidism at the Karolinska University Hospital 2005-2015 and treated with Lugol's solution were included. All electronic files were carefully reviewed manually, with focus on the cause of treatment and admission, demographic data, and effects of iodine on thyroid hormone levels and pulse frequency.

Results: Twenty-seven patients were included. Lugol's solution had been chosen due to agranulocytosis in 9 (33%), hepatotoxicity in 2 (7%), other side effects in 11 (41%) and poor adherence to medication in 5 (19%). Levels of free T4, free T3 and heart rate decreased significantly after 5-9 days of iodine therapy (free T4 53-20 pmol/L, P = 0.0002; free T3 20-6.5 pmol/L, P = 0.04; heart rate 87-76 beats/min P = 0.0007), whereas TSH remained unchanged. Side effects were noted in 4 (15%) (rash n = 2, rash and vomiting n = 1, swelling of fingers n = 1). Thyroidectomy was performed in 26 patients (96%) and one was treated with radioiodine; all treatments were without serious complications.

Conclusion: Treatment of uncontrolled hyperthyroidism with Lugol's solution before definitive treatment is safe and it decreases thyroid hormone levels and heart rate. Side effects were limited. Lugol's solution could be recommended pre-operatively in Graves' disease with failed medical treatment, especially if side effects to anti-thyroid drugs have occurred.

Keywords: Graves’ disease; Lugol’s solution; hyperthyroidism; iodine; potassium iodide.

© 2017 The authors.

Figures

Figure 1
Figure 1
Accumulative doses of iodine solution in 27 patients with uncontrolled Graves’ disease.
Figure 2
Figure 2
Initial TSH, free T4, free T3 and pulse, and changes during Lugol’s solution. *Indicates P < 0.05 compared to timepoint 0.

References

    1. Abraham P, Avenell A, McGeoch SC, Clark LF, Bevan JS. Antithyroid drug regimen for treating Graves’ hyperthyroidism. Cochrane Database of Systematic Reviews 2010. 1 CD003420 (10.1002/14651858.CD003420.pub4)
    1. Pearce EN. Diagnosis and management of thyrotoxicosis. BMJ 2006. 332 1369–1373. (10.1136/bmj.332.7554.1369)
    1. Plummer HS. The value of iodine in exopthalmic goiter. Journal of the Iowa Medical Society 1924. 14 66–73.
    1. Leung AM, Braverman LE. Consequences of excess iodine. Nature Reviews Endocrinology 2014. 10 136–142. (10.1038/nrendo.2013.251)
    1. Paul T, Meyers B, Witorsch RJ, Pino S, Chipkin S, Ingbar SH, Braverman LE. The effect of small increases in dietary iodine on thyroid function in euthyroid subjects. Metabolism 1988. 37 121–124. (10.1016/S0026-0495(98)90004-X)
    1. Wolff J, Chaikoff IL. Plasma inorganic iodide as a homeostatic regulator of thyroid function. Journal of Biological Chemistry 1948. 174 555–564.
    1. Eng PH, Cardona GR, Fang SL, Previti M, Alex S, Carrasco N, Chin WW, Braverman LE. Escape from the acute Wolff-Chaikoff effect is associated with a decrease in thyroid sodium/iodide symporter messenger ribonucleic acid and protein. Endocrinology 1999. 140 3404–3410. (10.1210/endo.140.8.6893)
    1. Leustean L, Preda C, Ungureanu MC, Danila R, Mogos V, Stefanescu C, Vulpoi C. Jod-Basedow effect due to prolonged use of Lugol solution-case report. Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi 2014. 118 1013–1017.
    1. Tan TT, Morat P, Ng ML, Khalid BA. Effects of Lugol’s solution on thyroid function in normals and patients with untreated thyrotoxicosis. Clinical Endocrinology 1989. 30 645–649. (10.1111/j.1365-2265.1989.tb00270.x)
    1. Erbil Y, Ozluk Y, Giris M, Salmaslioglu A, Issever H, Barbaros U, Kapran Y, Ozarmagan S, Tezelman S. Effect of Lugol solution on thyroid gland blood flow and microvessel density in the patients with Graves’ disease. Journal of Clinical Endocrinology and Metabolism 2007. 92 2182–2189. (10.1210/jc.2007-0229)
    1. Yilmaz Y, Kamer KE, Ureyen O, Sari E, Acar T, Karahalli O. The effect of preoperative Lugol’s iodine on intraoperative bleeding in patients with hyperthyroidism. Annals of Medicine and Surgery 2016. 9 53–57. (10.1016/j.amsu.2016.06.002)
    1. Turner P, Granville-Grossman KL. Effect of adrenergic receptor blockade of the tachycardia of thyrotoxicosis and anxiety state. Lancet 1965. 2 1316–1318. (10.1016/S0140-6736(65)92340-8)
    1. Adlerberth A, Stenstrom G, Hasselgren PO. The selective beta 1-blocking agent metoprolol compared with antithyroid drug and thyroxine as preoperative treatment of patients with hyperthyroidism. Results from a prospective, randomized study. Annals of Surgery 1987. 205 182–188. (10.1097/00000658-198702000-00013)
    1. Feek CM, Sawers JS, Irvine WJ, Beckett GJ, Ratcliffe WA, Toft AD. Combination of potassium iodide and propranolol in preparation of patients with Graves’ disease for thyroid surgery. New England Journal of Medicine 1980. 302 883–885. (10.1056/NEJM198004173021602)
    1. Schwartz AE, Clark OH, Ituarte P, Lo Gerfo P. Therapeutic controversy: thyroid surgery – the choice. Journal of Clinical Endocrinology and Metabolism 1998. 83 1097–1105. (10.1210/jcem.83.4.4740-1)
    1. Kaur S, Parr JH, Ramsay ID, Hennebry TM, Jarvis KJ, Lester E. Effect of preoperative iodine in patients with Graves’ disease controlled with antithyroid drugs and thyroxine. Annals of the Royal College of Surgeons of England 1988. 70 123–127.
    1. Shinall MC, Jr, Broome JT, Baker A, Solorzano CC. Is potassium iodide solution necessary before total thyroidectomy for Graves disease? Annals of Surgical Oncology 2013. 20 2964–2967. (10.1245/s10434-013-3126-z)
    1. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, et al. 2016. American Thyroid Association Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 2016. 26 1343–1421. (10.1089/thy.2016.0229)
    1. Falhammar H, Frisen L, Hirschberg AL, Norrby C, Almqvist C, Nordenskjold A, Nordenstrom A. Increased cardiovascular and metabolic morbidity in patients with 21-hydroxylase deficiency: a swedish population-based national cohort study. Journal of Clinical Endocrinology and Metabolism 2015. 100 3520–3528. (10.1210/JC.2015-2093)
    1. Pino S, Fang SL, Braverman LE. Ammonium persulfate: a safe alternative oxidizing reagent for measuring urinary iodine. Clinical Chemistry 1996. 42 239–243.
    1. Falhammar H, Thoren M, Calissendorff J. Thyrotoxic periodic paralysis: clinical and molecular aspects. Endocrine 2013. 43 274–284. (10.1007/s12020-012-9777-x)
    1. Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G. Rang and Dale’s Pharmacology, 7th ed. London, UK: Churchill Livingstone, 2010.
    1. Safran M, Braverman LE. Effect of chronic douching with polyvinylpyrrolidone-iodine on iodine absorption and thyroid function. Obstetrics and Gynecology 1982. 60 35–40.
    1. Walter MA, Briel M, Christ-Crain M, Bonnema SJ, Connell J, Cooper DS, Bucher HC, Muller-Brand J, Muller B. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ 2007. 334 514 (10.1136/)
    1. Alexander EK, Larsen PR. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves’ disease. Journal of Clinical Endocrinology and Metabolism 2002. 87 1073–1077. (10.1210/jcem.87.3.8333)
    1. Erem C, Kandemir N, Hacihasanoglu A, Ersoz HO, Ukinc K, Kocak M. Radioiodine treatment of hyperthyroidism: prognostic factors affecting outcome. Endocrine 2004. 25 55–60. (10.1385/ENDO:25:1:55)
    1. Berg GE, Michanek AM, Holmberg EC, Fink M. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements. Journal of Nuclear Medicine 1996. 37 228–232.
    1. Yang Y, Hwang S, Kim M, Lim Y, Kim MH, Lee S, Lim DJ, Kang MI, Cha BY. Refractory Graves’ disease successfully cured by adjunctive cholestyramine and subsequent total thyroidectomy. Endocrinology and Metabolism 2015. 30 620–625. (10.3803/EnM.2015.30.4.620)
    1. Baeza A, Aguayo J, Barria M, Pineda G. Rapid preoperative preparation in hyperthyroidism. Clinical Endocrinology 1991. 35 439–442. (10.1111/j.1365-2265.1991.tb03562.x)
    1. Huang SM, Liao WT, Lin CF, Sun HS, Chow NH. Effectiveness and mechanism of preoperative Lugol solution for reducing thyroid blood flow in patients with euthyroid Graves’ disease. World Journal of Surgery 2016. 40 505–509. (10.1007/s00268-015-3298-8)
    1. Hallgrimsson P, Nordenstrom E, Bergenfelz A, Almquist M. Hypocalcaemia after total thyroidectomy for Graves’ disease and for benign atoxic multinodular goitre. Langenbeck’s Archives of Surgery/Deutsche Gesellschaft fur Chirurgie 2012. 397 1133–1137. (10.1007/s00423-012-0981-1)
    1. Pesce CE, Shiue Z, Tsai HL, Umbricht CB, Tufano RP, Dackiw AP, Kowalski J, Zeiger MA. Postoperative hypocalcemia after thyroidectomy for Graves’ disease. Thyroid 2010. 20 1279–1283. (10.1089/thy.2010.0047)
    1. Philippou G, Koutras DA, Piperingos G, Souvatzoglou A, Moulopoulos SD. The effect of iodide on serum thyroid hormone levels in normal persons, in hyperthyroid patients, and in hypothyroid patients on thyroxine replacement. Clinical Endocrinology 1992. 36 573–578. (10.1111/j.1365-2265.1992.tb02267.x)
    1. Okamura K, Sato K, Fujikawa M, Bandai S, Ikenoue H, Kitazono T. Remission after potassium iodide therapy in patients with Graves’ hyperthyroidism exhibiting thionamide-associated side effects. Journal of Clinical Endocrinology and Metabolism 2014. 99 3995–4002. (10.1210/jc.2013-4466)

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere